Dr. Tianwei Ma plays a critical role in expanding our product portfolio and advancing early R&D programs to clinical development. Dr. Ma has more than 20 years of experience in drug discovery focusing on medicinal chemistry, and leading many discoveries program to achieve PCC or IND stage, and is listed as an inventor or co-inventor for approximately 30 granted patent applications.
During his Ph.D. research, Dr. Ma participated in the early discovery of Clevudine (Levovir®), an anti-HBV agent. He then spent nearly 20 years at Eli Lilly & Company, where he contributed to the delivery of multiple small molecule clinical candidates, while advancing from principal research scientist to director of chemistry. After his tenure at Eli Lilly & Company, Dr. Ma served in critical roles for two biotech companies, PegBio Co., Ltd. and BioFront Therapeutics as VP, head of chemistry, responsible for building and leading the team, product and portfolio design, implementation, and progression.
Dr. Ma obtained his Ph.D. degree in medicinal chemistry from the University of Georgia, and he has a Master of Science degree in medicinal chemistry from Beijing Medical Sciences University, which was later merged into Peking University.